Theralase Completes Enrollment of 90 Patients in Phase II Bladder Cancer Study for Light-Activated Ruvidar
核心洞察
Theralase has successfully completed enrollment of 90 patients in its Phase II clinical study evaluating light-activated Ruvidar for BCG-unresponsive non-muscle invasive bladder cancer.
The study targets patients with carcinoma in-situ who have failed standard-of-care therapy and are facing radical cystectomy as their only remaining option.
Clinical data generated to date demonstrates strong efficacy, duration of response and favorable safety profile, with a majority of patients achieving durable responses with a single treatment.
Theralase Technologies Inc. (搜索) has achieved a critical milestone in its bladder cancer program by completing enrollment of 90 patients in its Phase II clinical study evaluating light-activated Ruvidar for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The enrollment represents a significant step toward potential regulatory approval for patients with limited treatment alternatives.
Study Design and Patient Population
The multi-center Phase II clinical study is evaluating light-activated Ruvidar in patients diagnosed with Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC carcinoma in-situ (CIS) who have failed standard-of-care therapy and are facing radical cystectomy (bladder removal). The study has a primary endpoint of efficacy, a secondary endpoint of duration of response, and a tertiary endpoint of safety.
Study II utilizes the therapeutic dose of the small molecule Ruvidar, which has been light-activated by the TLC-3200 Medical Laser System. The study is being conducted across 12 clinical study sites located in Canada and the United States.
Clinical Significance and Unmet Medical Need
NMIBC is a form of bladder cancer found in the inner layer cells of the bladder that does not invade into or beyond the muscle wall. In the United States, bladder cancer is the sixth most common cancer and fourth among men, with an estimated 84,870 new cases expected in 2025. Historically, 75% of bladder cancer presents as NMIBC.
For patients with high-risk NMIBC, intravesical BCG remains the first-line standard-of-care. However, approximately one-third of patients with NMIBC will not respond to BCG therapy, and 50% of those with an initial response will experience recurrence or progression of their disease. Current treatment options for BCG-unresponsive patients are very limited, with National Comprehensive Cancer Network guidelines recommending cystectomy (partial or complete removal of the bladder).
Promising Clinical Results
Clinical data generated to date continues to demonstrate a strong efficacy, duration of response and favorable safety profile, with a majority of patients achieving durable responses with a single treatment. The enrollment of 90 patients achieves the company's statistical analysis plan and represents a significant step forward in evaluating a statistically and clinically significant dataset in support of Health Canada and FDA regulatory approval.
Leadership Perspectives
Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase, stated, "I am pleased that Theralase has completed enrollment of 90 patients in its Phase II registrational clinical study for bladder cancer. This accomplishment allows the Company to complete this study in 2026 and prepare for Health Canada and FDA regulatory approval submissions."
Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase, added, "Enrolling and treating 90 patients in our Phase II registration clinical study represents a significant milestone for the Company. With the targeted enrollment now completed, we can focus on compilation of the clinical data for Health Canada and FDA regulatory approval. 2026 will be a pivotal year for the Company as we complete our bladder cancer study, embark on a combinational clinical study for bladder cancer and launch numerous Phase I/II adaptive clinical studies for brain, lung, muscle invasive bladder, pancreatic and colorectal cancers."
Regulatory Path Forward
Pending Health Canada and FDA regulatory approval, light-activated Ruvidar represents a potentially transformative, bladder-sparing treatment option for patients with limited alternatives, addressing a significant unmet need in high-risk NMIBC. The company plans to complete the study in 2026 and prepare regulatory submissions.
Technology Platform
Ruvidar is a small molecule activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses. Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds and their formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue.